CONMED CFO Todd Garner to Depart, Transitioning to Special Advisor Role
CNMD sits 15% above its 52-week low of $38.32.
Summary
CONMED Corporation's CFO, Todd Garner, is stepping down, but will remain with the company as a Special Advisor through November 2026 to ensure a smooth transition, with no disagreements cited as the reason for his departure.
Key Events · Executive and Board Changes · CNMD
-
CFO Departure Announced
Todd Garner will cease to be Chief Financial Officer by March 15, 2026, or upon the appointment of a new permanent CFO, whichever is earlier.
-
Smooth Transition Plan
Mr. Garner will transition to a non-executive Special Advisor role and remain employed until November 2, 2026, to ensure an orderly handover.
-
No Disagreements Cited
The company explicitly stated that the separation did not arise from any disagreements regarding operations, policies, financial results, or accounting practices.
-
Severance and Equity Vesting
Mr. Garner will receive severance benefits, including 1.5 times his base salary and average annual bonus, plus COBRA continuation. His outstanding equity awards will continue to vest through November 2, 2026.
Analysis · CNMD · Industrial Applications And Services
CONMED Corporation announced the planned departure of its Chief Financial Officer, Todd Garner, with a structured transition period. While a change in a key executive role like CFO can introduce uncertainty, the company explicitly stated that the separation did not stem from any disagreements regarding operations, policies, financial results, or accounting practices. Mr. Garner will remain as CFO until a successor is appointed (by March 15, 2026, at the latest) and then transition to a Special Advisor role until November 2, 2026, ensuring a smooth handover. This managed transition and the absence of underlying financial disputes mitigate the potential negative impact of the leadership change.
At the time of this filing, CNMD was trading at $44.20 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $38.32 to $74.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.